Zhipeng Wang
-
- Natural Compounds in Disease Treatment 6
- Cancer Research top 10%
- Cancer, Hypoxia, and Metabolism 6
- Oncology top 10%
- Drug Transport and Resistance Mechanisms 7
- Cancer-related Molecular Pathways 5
- Molecular Biology top 10%
- Cancer therapeutics and mechanisms 8
- Epigenetics and DNA Methylation 5
- Pharmacology top 5%
- Pharmacogenetics and Drug Metabolism 6
- Antibiotics Pharmacokinetics and Efficacy 5
- Journals
- Nature Communications (1 paper)Journal of Clinical Oncology (1 paper)SHILAP Revista de lepidopterología (1 paper)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Zhipeng Wang
98 papers receiving 1.5k citations
Peers
Comparison fields: 5 of 135
- Complementary and alternative medicine 200
- Cancer Research 249
- Oncology 330
- Molecular Biology 765
- Pharmacology 92
Countries citing papers authored by Zhipeng Wang
This map shows the geographic impact of Zhipeng Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhipeng Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhipeng Wang more than expected).
Fields of papers citing papers by Zhipeng Wang
This network shows the impact of papers produced by Zhipeng Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhipeng Wang. The network helps show where Zhipeng Wang may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Zhipeng Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 4 | |
| 2 | 2025 | 2 | |
| 3 | 2025 | 1 | |
| 4 | 2024 | 7 | |
| 5 | 2024 | 2 | |
| 6 | 2024 | 4 | |
| 7 | 2024 | 5 | |
| 8 | 2024 | 3 | |
| 9 | 2023 | 3 | |
| 10 | 2023 | 2 | |
| 11 | 2022 | 6 | |
| 12 | 2021 | 0 | |
| 13 | 2018 | 4 | |
| 14 | 2017 | 6 | |
| 15 | 2016 | 55 | |
| 16 | 2013 | 48 | |
| 17 | Effect of Triptolide on Gene Expression Profile of Colon Cancer Cells SW480 | 2012 | 1 |
| 18 | 2012 | 46 | |
| 19 | 2011 | 8 | |
| 20 | 2011 | 1 |
About Zhipeng Wang
Zhipeng Wang is a scholar working on Pharmacology, Complementary and alternative medicine and Oncology, having authored 103 papers that have together received 1.5k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (8 papers), Drug Transport and Resistance Mechanisms (7 papers), Pharmacogenetics and Drug Metabolism (6 papers), Natural Compounds in Disease Treatment (6 papers), Cancer, Hypoxia, and Metabolism (6 papers), Cancer-related Molecular Pathways (5 papers), Antibiotics Pharmacokinetics and Efficacy (5 papers) and Epigenetics and DNA Methylation (5 papers). The work is most often cited by research in Complementary and alternative medicine (200 citations), Cancer Research (249 citations) and Oncology (330 citations). Zhipeng Wang has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Qibing Mei, Qijia Xuan, Daiming Fan, Haifeng Jin, Wansheng Chen, Shouhong Gao, Xin Lian, Ruodan Xu, Zhifu Yang and Hang Liu. Their work appears in journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.